16 results
Search Results
Now showing 1 - 10 of 16
Item Open Access A study of piano accompanying technique and aspects of Neo-Classicism in Paul Hindemith's sonata for viola and piano, op.11 no.4(Mahidol University, 2022) Sara, Choi, 1986 -; Fry, Kyle; Ampai Buranaprapuk.This thematic paper is a study and analysis of the Sonata for Viola and Piano, Op. 11, No. 4, which was composed in 1919 by Paul Hindemith. This piece is one of his early works and it contains aspects of the late Romantic form of Brahms and Reger... in the introduction with a romantic melodic theme. It features frequent enharmonic modulation, nonharmonic tones, varied chords and altered chords in the first movement. The theme is exchanged between the viola and piano parts. The second movement consists of fourItem Metadata only Graduate Viola recital(Mahidol University. Mahidol University Library and Knowledge Center, 2011) Suppaporn Suwanpakdee; James Ogburn; Schaub Christopherการแสดงเดี่ยววิโอล่าระดับบัณฑิตศึกษานี้มีวัตถุประสงค์เพื่อพัฒนาศักยภาพและทักษะ การแสดงของผู้แสดงเดี่ยวโดยผ่านทางกระบวนการวิจัย และเพื่อให้ผู้แสดงเรียนรู้การจัดการแสดงอีกทั้ง เขียนสูจิบัตรโดยเนื้อหาเกี่ยวข้องกับบทประพันธ์ที่ผู้แสดงเลือก ประวัติศาสตร์ทางดนตรีของ บทประพันธ์ รวมถึงประวัติของผู้ประพัน;Item Metadata only Covered assets : tenured heads of Music Institutions Composers for viola pieces(Mahidol University. Mahidol University Library and Knowledge Center, 2024) Visintin, Giacomo, 1984-; Keasler, Daniel Jacob; Phuttaraksa KamnirdratanaWhat does writing for viola solo mean for a composer? From where does this particular will to give voice to this particular instrument come? Nowadays, we can state that the viola has gained its full redemption in the universe of classic music after... centuries of jokes about its performers. So, then, what happens when the particular inspiration to write viola pieces is merged with the figure of the Dean, namely the one who is in charge of the top of the chain of a music institution? This researchItem Metadata only Graduate viola recital by Annop Ruangmanee(Mahidol University. Mahidol University Library and Knowledge Center, 2010) Annop Ruangmanee; Paul Cesarczyk; Schaub ChristopherItem Metadata only คีตกาล ตอน 22 : คอนเสิร์ต Master of the Violaสถานีโทรทัศน์ Mahidol Channel; มหาวิทยาลัยมหิดล. สำนักงานอธิการบดีItem Open Access A performance and pedagogical guide for the viola sonata op.147 by Dmirti Shostakovich(Mahidol University, 2022) Krit Supabpanich; Ampai Buranaprapuk; Fry, KyleThe purpose of this thematic paper is to provide a performance and pedagogical guide for the Viola Sonata, Op. 147 by Dmitri Shostakovich. This thematic paper aims to guide performers with respect to interpretation and understanding the historical... from each of the three movements of the Shostakovich Viola Sonata with illustrations from the score and it will provide examples of how to teach and practice based on the author’s research, covering issues such as ensemble concerns between the violistItem Metadata only Accompaniment Guide: Brahms’ Scherzo from FAE Sonata(2025-07-01) Prommachart P.; Rajatanavin T.; Prommachart P.; Mahidol UniversityDue to the similar resemblance of their ranges, Johannes Brahms’ Scherzo from the FAE Sonata can be performed on both violin and viola. While the differences between the sounds of two string instruments may be hardly noticeable to the untrained ears..., piano accompanists must remain adaptable to changes in timbre and other technical aspects when the viola assumes the solo role. This article demonstrates that the shift in instrumentation results in a significantly altered creative outcome, especiallyItem Metadata only คีตกาล ตอน 31 : คอนเสิร์ต Violin & Violaสถานีโทรทัศน์ Mahidol Channel; มหาวิทยาลัยมหิดล. สำนักงานอธิการบดีPublication Metadata only The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable(2017-01-01) Thanyanan Reungwetwattana; Ying Liang; Viola Zhu; Sai Hong Ignatius Ou; Mahidol University; Sun Yat-Sen University Cancer Center; VA Medical Center; UCI Medical Center© 2016 The Author(s) A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for the treatment of non-small cell lung cancers (NSCLC), including those targeted against epidermal growth factor receptor, anaplastic lymphoma kinase, and ROS1. Despite a wealth of agents developed to target the receptor tyrosine kinase, MET, clinical outcomes have as yet been disappointing, leading to pessimism about the role of MET in the pathogenesis of NSCLC. However, in recent years, there has been a renewed interest in MET exon 14 alterations as potential drivers of lung cancer. MET exon 14 alterations, which result in increased MET protein levels due to disrupted ubiquitin-mediated degradation, occur at a prevalence of around 3% in adenocarcinomas and around 2% in other lung neoplasms, making them attractive targets for the treatment of lung cancer. At least five MET-targeted TKIs, including crizotinib, cabozantinib, capmatinib, tepotinib, and glesatinib, are being investigated clinically for patients with MET exon 14 altered-NSCLC. A further two compounds have shown activity in preclinical models. In this article, we review the current clinical and preclinical data available for these TKIs, along with a number of other potential therapeutic options, including antibodies and immunotherapy. A number of questions remain unanswered regarding the future of MET TKIs, but unfortunately, the development of resistance to targeted therapies is inevitable. Resistance is expected to arise as a result of receptor tyrosine kinase mutation or from upregulation of MET ligand expression; potential strategies to overcome resistance are proposed.Publication Metadata only An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC(2020-01-01) Viola W. Zhu; Yen Ting Lin; Dong Wan Kim; Herbert H. Loong; Misako Nagasaka; Hao To; Yvonne Li En Ang; Chan Young Ock; Nishan Tchekmedyian; Sai Hong Ignatius Ou; Nicholas L. Syn; Thanyanan Reungwetwattana; Chia Chi Lin; Ross A. Soo; National Taiwan University Hospital; Yong Loo Lin School of Medicine; National Taiwan University College of Medicine; Seoul National University Hospital; Wayne State University School of Medicine; National University of Singapore; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; UCI School of Medicine; University of Nevada School of Medicine; Chinese University of Hong Kong; Pacific Shores Medical Group© 2020 International Association for the Study of Lung Cancer Introduction: Lorlatinib, a next-generation central nervous system–penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study. Methods: A real-world analysis was performed on ALK+ or ROS1-positive (ROS1+) patients with NSCLC enrolled in lorlatinib early or expanded access programs in Hong Kong, Singapore, South Korea, Taiwan, Thailand, and the United States. Results: A total of 95 patients with NSCLC (76 ALK+ and 19 ROS1+) were analyzed. Among ALK+ patients treated with less than two previous TKIs, two or more previous TKIs, and three or more previous TKIs, the objective response rates (ORR) and median progression-free survival (mPFS) were 42% (95% confidence interval [CI]: 26–59; n = 38) and not reached (NR) (95% CI: 4.5–NR; n = 45), 35% (95% CI: 22–49; n = 55) and 11.2 months (95% CI: 4.5–NR; n = 66), and 18% (95% CI: 4–43; n = 17) and 6.5 months (95% CI: 3.5–11.6; n = 21), respectively. The ORRs and mPFSs were 13% (95% CI: 0–53; n = 8) and 9.2 months (95% CI: 3.3–NR; n = 9) for patients treated with one second-generation ALK TKI as the only ALK TKI received. For ROS1+ patients, ORRs and mPFSs were 41% (95% CI: 18–67; n = 17) and 11.9 months (95% CI: 6.4–NR; n = 19). The intracranial ORRs were 35% (95% CI: 22–49) and 55% (95% CI: 23–83) for 52 ALK+ and 11 ROS1+ patients. mPFS was 9.3 months (95% CI: 1.0–NR; n = 13) for patients with leptomeningeal carcinomatosis. No new safety signals were noted. Conclusion: Lorlatinib exhibited meaningful activity in TKI-refractory ALK+ or ROS1+ patients with NSCLC enrolled in early or expanded access programs.